October 2, 2018 10:16 AM EDT

F-Prime's Ben Auspitz co-leads $30M Series A with OrbiMed for his latest rare disease venture

Amber Tong

Having spent his 13 years at F-Prime Partners backing and advising rare disease companies — including Dimension Therapeutics and Orchard Therapeutics, which he co-founded — Ben Auspitz …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

F-Prime's Ben Auspitz co-leads $30M Series A with OrbiMed for his latest rare disease venture

Amber Tong

Sign up to read this article for free.

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Alector says Alzheimer's program targeting microglia fails Phase 2, stock dives

Food allergy biotech Alladapt closes after Phase 3 talks with FDA

Roche’s TIGIT drug misses last shot at survival endpoint win in Phase 3 lung cancer trial

F-Prime's Ben Aus­pitz co-leads $30M Se­ries A with Or­biMed for his lat­est rare dis­ease ven­ture

Amber Tong

Sign up to read this article for free.

more like this

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Alec­tor says Alzheimer's pro­gram tar­get­ing mi­croglia fails Phase 2, stock dives

Food al­ler­gy biotech Al­ladapt clos­es af­ter Phase 3 talks with FDA

Roche’s TIG­IT drug miss­es last shot at sur­vival end­point win in Phase 3 lung can­cer tri­al

F-Prime's Ben Auspitz co-leads $30M Series A with OrbiMed for his latest rare disease venture

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Alector says Alzheimer's program targeting microglia fails Phase 2, stock dives

Food allergy biotech Alladapt closes after Phase 3 talks with FDA

Roche’s TIGIT drug misses last shot at survival endpoint win in Phase 3 lung cancer trial